Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Aurobindo Pharma Ltd ( (IN:AUROPHARMA) ).
Aurobindo Pharma Limited announced the completion of a US FDA inspection at Unit-I of its wholly owned subsidiary, Apitoria Pharma Private Limited, located in Telangana, India. The inspection concluded with a ‘Form 483’ issued containing five procedural observations, but no data integrity issues were found. The company stated that these observations will not impact its financials or operations, reaffirming its commitment to maintaining high-quality manufacturing standards.
More about Aurobindo Pharma Ltd
Aurobindo Pharma Limited is a prominent player in the pharmaceutical industry, focusing on the development, manufacturing, and marketing of generic pharmaceuticals and active pharmaceutical ingredients (APIs). The company operates globally, providing a wide range of products across various therapeutic segments.
Average Trading Volume: 36,394
Technical Sentiment Signal: Hold
Current Market Cap: 597.4B INR
See more data about AUROPHARMA stock on TipRanks’ Stock Analysis page.